Delcath Systems raised its full-year 2026 revenue guidance to a range of $104 million to $108 million, reflecting strong first-half performance and continued growth in HEPZATO KIT volume. Second-quarter revenue rose 20% year over year to $29.1 million, with HEPZATO KIT revenue of $27.1 million. HEPZATO volume increased 17% sequentially from the first quarter and 30% year over year. The company ended the quarter with 31 active treatment centers and remains on track to reach approximately 37 by year-end. Delcath also reported net income of $2.7 million and adjusted EBITDA of $7.6 million, while advancing Phase II trials in metastatic colorectal and HER2-negative breast cancer despite slower-than-expected enrollment.
Delcath Systems IncRaises 2026 revenue guidance and reports strong Q2 results with net income and adjusted EBITDA.
